Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Live-cell phenotypic-biomarker microfluidic assay for the risk stratification of cancer patients via machine learning.

Manak MS, Varsanik JS, Hogan BJ, Whitfield MJ, Su WR, Joshi N, Steinke N, Min A, Berger D, Saphirstein RJ, Dixit G, Meyyappan T, Chu HM, Knopf KB, Albala DM, Sant GR, Chander AC.

Nat Biomed Eng. 2018 Oct;2(10):761-772. doi: 10.1038/s41551-018-0285-z. Epub 2018 Sep 17.

2.

Live-single-cell phenotypic cancer biomarkers-future role in precision oncology?

Sant GR, Knopf KB, Albala DM.

NPJ Precis Oncol. 2017 Jun 15;1(1):21. doi: 10.1038/s41698-017-0025-y. eCollection 2017. Review.

3.

Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia.

Noxon V, Knopf KB, Norris LB, Chen B, Yang YT, Qureshi ZP, Hrushesky W, Lebby AA, Schooley B, Hikmet N, Dickson M, Thamer M, Cotter D, Yarnold PR, Bennett CL.

J Oncol Pract. 2017 Jun;13(6):e562-e573. doi: 10.1200/JOP.2016.019364. Epub 2017 May 15.

4.

Characteristics and treatment patterns among US patients with hairy cell leukemia: a retrospective claims analysis.

Divino V, Karve S, Gaughan A, DeKoven M, Gao G, Knopf KB, Lanasa MC.

J Comp Eff Res. 2017 Sep;6(6):497-508. doi: 10.2217/cer-2017-0014. Epub 2017 May 9.

5.

Economic Burden of Tyrosine Kinase Inhibitor Treatment Failure in Chronic Myeloid Leukemia.

Knopf KB, Divino V, McGarry L, Chen YJ, Pokras S, Munakata J, Taylor C, Ng D, Nieset C, Huang H.

Clin Lymphoma Myeloma Leuk. 2015 Nov;15(11):e163-71. doi: 10.1016/j.clml.2015.07.647. Epub 2015 Aug 5.

PMID:
26411541
6.

Adding Bevacizumab to the Treatment of Patients With Non-Small-Cell Lung Cancer: Caveat Emptor.

Hermanson TT, Hrushesky WJ, Knopf KB, Bennett CL.

J Oncol Pract. 2015 Sep;11(5):363-4. doi: 10.1200/JOP.2015.005397. Epub 2015 Aug 4. No abstract available.

PMID:
26243648
7.

Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma.

Knopf KB, Duh MS, Lafeuille MH, Gravel J, Lefebvre P, Niculescu L, Ba-Mancini A, Ma E, Shi H, Comenzo RL.

Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):380-8. doi: 10.1016/j.clml.2014.03.005. Epub 2014 Jun 11.

PMID:
25023616
8.

Defining Value in Cancer Care: AVBCC 2013 Steering Committee Report.

AVBCC 2013 Steering Committee: Co-Chairs, Zweigenhaft B, Bosserman L, Kenney JT Jr, Lawless GD, Marsland TA, Deligdish CK, Burgoyne DS, Knopf KB, Long DM, McKercher P, Owens GM, Hennessy JE, Lang JR, Malin J, Natelson L, Palmgren MC, Slotnik J, Shockney LD, Vogenberg FR.

Am Health Drug Benefits. 2013 Jul;6(5):236-46.

9.

The safety of bendamustine in patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma and concomitant renal impairment: a retrospective electronic medical record database analysis.

Nordstrom BL, Knopf KB, Teltsch DY, Engle R, Beygi H, Sterchele JA.

Leuk Lymphoma. 2014 Jun;55(6):1266-73. doi: 10.3109/10428194.2013.836600. Epub 2013 Oct 3.

PMID:
23987821
10.

Thrombocytopenia in the intensive care unit.

Wang HL, Aguilera C, Knopf KB, Chen TM, Maslove DM, Kuschner WG.

J Intensive Care Med. 2013 Sep-Oct;28(5):268-80. doi: 10.1177/0885066611431551. Epub 2012 Jan 9. Review.

PMID:
22232201
11.

Health care utilization and mortality among elderly patients with myelodysplastic syndromes.

Lindquist KJ, Danese MD, Mikhael J, Knopf KB, Griffiths RI.

Ann Oncol. 2011 May;22(5):1181-8. doi: 10.1093/annonc/mdq552. Epub 2010 Nov 1.

12.

Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer.

Stokes ME, Muehlenbein CE, Marciniak MD, Faries DE, Motabar S, Gillespie TW, Lipscomb J, Knopf KB, Buesching DP.

J Manag Care Pharm. 2009 Oct;15(8):669-82.

13.

Multiple significant bortezomib-related toxicities in one patient: case report and literature review.

Waller JM, Moretto JC, Knopf KB.

Clin Lymphoma Myeloma. 2009 Jun;9(3):E1-4. doi: 10.3816/CLM.2009.n.051.

PMID:
19525183
14.

Value and use of economic evaluation in oncology.

Knopf KB, Hutton J.

J Clin Oncol. 2007 Dec 10;25(35):5666-7; author reply 5667. No abstract available.

PMID:
18065743
15.

Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer.

Paramore LC, Thomas SK, Knopf KB, Cragin LS, Fraeman KH.

Clin Colorectal Cancer. 2006 May;6(1):52-8.

PMID:
16796792
16.

Racial differences in the receipt of bowel surveillance following potentially curative colorectal cancer surgery.

Ellison GL, Warren JL, Knopf KB, Brown ML.

Health Serv Res. 2003 Dec;38(6 Pt 2):1885-903.

17.

The prevalence of patients with colorectal carcinoma under care in the U.S.

Mariotto A, Warren JL, Knopf KB, Feuer EJ.

Cancer. 2003 Sep 15;98(6):1253-61.

18.

Utility of the SEER-Medicare data to identify chemotherapy use.

Warren JL, Harlan LC, Fahey A, Virnig BA, Freeman JL, Klabunde CN, Cooper GS, Knopf KB.

Med Care. 2002 Aug;40(8 Suppl):IV-55-61.

PMID:
12187169
19.

Bowel surveillance patterns after a diagnosis of colorectal cancer in Medicare beneficiaries.

Knopf KB, Warren JL, Feuer EJ, Brown ML.

Gastrointest Endosc. 2001 Nov;54(5):563-71.

PMID:
11677471
20.

The control of prostate-specific antigen expression and gene regulation by pharmacological agents.

Dixon SC, Knopf KB, Figg WD.

Pharmacol Rev. 2001 Mar;53(1):73-91. Review.

PMID:
11171939
21.

Hodgkin's disease and HIV infection.

Knopf KB, Locker GY.

N Engl J Med. 1995 Jul 6;333(1):65-6. No abstract available.

PMID:
7777005

Supplemental Content

Loading ...
Support Center